Anticancer Ruthenium Complexes with HDAC Isoform Selectivity

Cross, J.M.; Blower, T.R.; Kingdon, A.D.H.; Pal, R.; Picton, D.M.; Walton, J.W.

doi:10.3390/molecules25102383

Anticancer Ruthenium Complexes with HDAC Isoform Selectivity

Cross, J.M.; Blower, T.R.; Kingdon, A.D.H.; Pal, R.; Picton, D.M.; Walton, J.W.

Authors

J.M. Cross

Professor Tim Blower timothy.blower@durham.ac.uk
Professor

A.D.H. Kingdon

Professor Robert Pal robert.pal@durham.ac.uk
Professor

David Picton david.m.picton@durham.ac.uk
PGR Student Doctor of Philosophy

Dr James Walton james.walton@durham.ac.uk
Associate Professor

Abstract

The histone deacetylase (HDAC) enzymes have emerged as an important class of molecular targets in cancer therapy, with five inhibitors in clinical use. Recently, it has been shown that a lack of selectivity between the 11 Zn-dependent HDAC isoforms may lead to unwanted side-effects. In this paper, we show that piano stool Ru complexes can act as HDAC inhibitors, and variation in the capping arene leads to differences in HDAC isoform selectivity.

Citation

Cross, J., Blower, T., Kingdon, A., Pal, R., Picton, D., & Walton, J. (2020). Anticancer Ruthenium Complexes with HDAC Isoform Selectivity. Molecules, 25(10), Article 2383. https://doi.org/10.3390/molecules25102383

Journal Article Type	Article
Acceptance Date	May 16, 2020
Online Publication Date	May 21, 2020
Publication Date	May 2, 2020
Deposit Date	May 18, 2020
Publicly Available Date	May 22, 2020
Journal	Molecules
Publisher	MDPI
Peer Reviewed	Peer Reviewed
Volume	25
Issue	10
Article Number	2383
DOI	https://doi.org/10.3390/molecules25102383

Files

Published Journal Article (1.3 Mb)
PDF

Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/

Copyright Statement
2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).